focus -WSS

focus

author：explore 2025-09-29 01:38:14 - browse：8713

The FDA building -- First Opinion coverage from STAT — Adobe

The Food and Drug Administration on Monday approved a gene therapy for metachromatic leukodystrophy, a devastating genetic disorder that eats away at affected children’s neurons.

The medicine, marketed as Lenmeldy, is the first treatment for MLD, which is otherwise fatal. Lenmeldy has to be given before symptoms appear or, in some cases, after the first signs of disease, so it won’t be helpful for many patients living with MLD today. But when given in time, it appears to be near-curative, allowing some children to grow up and attend school with unaffected peers.

Lenmeldy is already marketed in Europe, under the name Libmeldy, and has helped a handful of patients in the U.S. who were treated under compassionate use, as their doctors feared they didn’t have time to wait for approval.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Readout LOUD podcast: brain research, obesity drug sales, Novartis

WSS

Anthos stroke drug appears safer than common blood thinner

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

CRISPR pioneers react to Casgevy, first gene

Steward Health Care files for bankruptcy

Apple Watch's A

Dairy farmers resist CDC push for PPE against bird flu virus

hotspot

focus

focus

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Weight loss drug costs may need more research, senator suggests

Novavax promises a turnaround & Lilly roils the obesity market

Poor hospice wound care hurts patients and families

FDA approval of Sarepta Duchenne genetic therapy gives me hope

First recipient of genetically engineered pig kidney has died

Activists slam private health insurers over coverage restrictions

CRISPR pioneers react to Casgevy, first gene

Wikipedia

Readout LOUD podcast: A CRISPR milestone, biotech mixology

CDC wastewater surveillance dashboard to track bird flu hotspots

Study: AI not yet building 'n

A daunting task: navigating dual Medicare, Medicaid eligibility

Study: Adult vaccinations pay for themselves in societal benefits

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

focus

hotspot

leisure time

entertainment